Ikena Oncology Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Mark Manfredi
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 45.9% |
| CEO tenure | 6.6yrs |
| CEO ownership | n/a |
| Management average tenure | 1.5yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)
Jun 01
Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%
Nov 10Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers
Aug 15Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues
May 20Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?
Apr 29We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully
Jan 06Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth
Aug 06Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts
Mar 23Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 21Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?
Feb 19We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate
Nov 02Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans
Jul 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$70m |
| Dec 31 2023 | US$1m | US$569k | -US$68m |
| Sep 30 2023 | n/a | n/a | -US$63m |
| Jun 30 2023 | n/a | n/a | -US$63m |
| Mar 31 2023 | n/a | n/a | -US$66m |
| Dec 31 2022 | US$2m | US$546k | -US$69m |
| Sep 30 2022 | n/a | n/a | -US$52m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$41m |
| Dec 31 2021 | US$5m | US$530k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$63m |
| Jun 30 2021 | n/a | n/a | -US$55m |
| Mar 31 2021 | n/a | n/a | -US$47m |
| Dec 31 2020 | US$606k | US$410k | -US$44m |
Compensation vs Market: Mark's total compensation ($USD1.24M) is above average for companies of similar size in the US market ($USD703.12K).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Manfredi (53 yo)
6.6yrs
Tenure
US$1,240,640
Compensation
Dr. Mark Manfredi, Ph D., serves as Member of Scientific Advisory Board of Bantam Pharmaceutical, LLC. He has been President, Chief Executive Officer and Director of Ikena Oncology, Inc. since December 201...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.6yrs | US$1.24m | no data | |
| CFO & Head of Corporate Development | 2.3yrs | US$782.32k | 0% $ 0 | |
| Senior Vice President of Finance & Operations | 1.6yrs | no data | no data | |
| Vice President of Investor Relations | less than a year | no data | no data | |
| Chief Development Officer | 2.7yrs | no data | no data | |
| VP & Head of Quality | 1.5yrs | no data | no data | |
| Senior Vice President of Clinical Development Operations | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Senior Vice President of Technical Operations | less than a year | no data | no data |
1.5yrs
Average Tenure
52.5yo
Average Age
Experienced Management: IKNA's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.6yrs | US$1.24m | no data | |
| Independent Director | 8.3yrs | US$130.36k | 0% $ 0 | |
| Chair of Scientific Advisory Board | 3.7yrs | no data | no data | |
| Independent Director | 3.6yrs | US$128.25k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data | |
| Chairman of the Board | 1.5yrs | US$167.86k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$131.86k | 0% $ 0 | |
| Independent Director | 7.7yrs | US$126.97k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$117.86k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data | |
| Independent Director | 3.3yrs | US$117.86k | 0% $ 0 |
3.7yrs
Average Tenure
62.5yo
Average Age
Experienced Board: IKNA's board of directors are considered experienced (3.7 years average tenure).